14.2 C
London
Saturday, October 19, 2024
HomeTagsEisai

Tag: Eisai

spot_imgspot_img

Japan – Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced Eisai has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...

Japan – Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

Astellas Pharma Inc. (TSE: 4503), Eisai Co., Ltd. (TSE: 4523), Daiichi Sankyo Company, Limited (TSE: 4568) and Takeda Pharmaceutical Company Limited. (TSE: 4502/...

Japan – Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals

Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic...

Japan – Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for...

Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration...

Japan – Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be...

Japan – Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone...

Japan – Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with...

Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img